Study: Nuplazid Demonstrates its Impact in Parkinson’s Disease Patients
According to a recent article in Parkinson’s News Today, results of an extension study confirm that FDA approved Nuplazid (pimavanserin) reduces the severity of delusions and hallucinations in Parkinson’s disease…